Antigen processing and presentation‐related signature‐derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation
Yang Chen, Yajie Cao, Song Wu, Xu Cao, Ting Cai, Hai Hu- Genetics (clinical)
- Drug Discovery
- Genetics
- Molecular Biology
- Molecular Medicine
Abstract
Background
In recent decades, osteosarcoma has remained the most prevalent kind of malignant tumor. An important and crucial factor in immunotherapy is antigen processing and presentation (APP). The specific functions and pathogenic processes of APP in osteosarcoma have not, however, been studied.
Methods
Patients with osteosarcoma were divided into groups using APP‐related genes. Machine learning was used to further build the APP‐related score. Investigated in‐depth were the prognostic relevance of the score, mutation features, immunological aspects, and pharmacological prediction performance. Investigations of the prognostic utility, immunological traits, drug prediction effectiveness and immunotherapy prediction of BNIP3 were performed in‐depth.
Results
Investigations by cell counting kit‐8, Transwell and 5‐ethynyl‐2‐deoxyuridine (EdU) demonstrated that BNIP3 is an osteosarcoma tumor accelerator. The osteosarcoma gene BNIP3 may promote macrophage migration. The APP‐related score shows potential for clinical use.
Conclusions
It was anticipated that more in vitro and in vivo studies would confirm BNIP3’s tumorigenic and immunogenic processes in osteosarcoma.